BioCentury | Aug 8, 2011
Product Development

HIV Trojan horse

...in places that drugs can't reach has helped the virus remain resistant to eradication. But Virxsys Corp....
...among key opinion leaders," according to Lawrence Michaelis, chairman and interim president and CEO of Virxsys...
...replication. The next step is to see if the efficacy translates into humans. Michaelis said Virxsys...
BioCentury | Jun 13, 2011
Company News

BioCis Pharma Ltd., Lx Therapies deal

...form Laurantis Pharma Oy . The newco hired Riku Rautsola, former president and CEO of Virxsys Corp....
BioCentury | Oct 4, 2010
Clinical News

Virxsys preclinical data

...Virxsys plans to submit an IND for VRX1273, a lentiviral vector-based HIV vaccine, by mid-2011. Virxsys Corp....
BioCentury | Aug 9, 2010
Clinical News

Virxsys preclinical data

...Vienna. Virxsys plans to submit an IND for the lentiviral vector-based HIV vaccine by mid-2011. Virxsys Corp....
BioCentury | Jun 7, 2010
Clinical News

Virxsys preclinical data

...Data were presented at the American Society of Gene and Cell Therapy meeting in Washington. Virxsys Corp....
BioCentury | May 31, 2010
Clinical News

Lexgenleucel-T: Phase II data

...Data were presented at the American Society of Gene and Cell Therapy meeting in Washington. Virxsys Corp....
BioCentury | Feb 22, 2010
Clinical News

Lexgenleucel-T: Phase I/II data

...antiretroviral therapy. Data were presented at the Retroviruses and Opportunistic Infections meeting in San Francisco. Virxsys Corp....
BioCentury | Feb 22, 2010
Clinical News

Virxsys preclinical data

...Infections meeting in San Francisco. VRX1023 is an HIV-based lentiviral vector that delivers HIV antigens. Virxsys Corp....
BioCentury | Sep 17, 2009
Cover Story

Rational attack on HIV

...broader response involving other immune cells. Gary McGarrity, EVP of scientific and clinical affairs at Virxsys Corp....
...have antibodies in the serum, but are they present on the mucosal surface?" he asked. Virxsys'...
...gp120 epitope identified by the IAVI team is within the viral genome region targeted by Virxsys'...
BioCentury | Feb 16, 2009
Clinical News

Lexgenleucel-T: Phase I/II data

...modified cells. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Montreal. Virxsys Corp....
Items per page:
1 - 10 of 31
BioCentury | Aug 8, 2011
Product Development

HIV Trojan horse

...in places that drugs can't reach has helped the virus remain resistant to eradication. But Virxsys Corp....
...among key opinion leaders," according to Lawrence Michaelis, chairman and interim president and CEO of Virxsys...
...replication. The next step is to see if the efficacy translates into humans. Michaelis said Virxsys...
BioCentury | Jun 13, 2011
Company News

BioCis Pharma Ltd., Lx Therapies deal

...form Laurantis Pharma Oy . The newco hired Riku Rautsola, former president and CEO of Virxsys Corp....
BioCentury | Oct 4, 2010
Clinical News

Virxsys preclinical data

...Virxsys plans to submit an IND for VRX1273, a lentiviral vector-based HIV vaccine, by mid-2011. Virxsys Corp....
BioCentury | Aug 9, 2010
Clinical News

Virxsys preclinical data

...Vienna. Virxsys plans to submit an IND for the lentiviral vector-based HIV vaccine by mid-2011. Virxsys Corp....
BioCentury | Jun 7, 2010
Clinical News

Virxsys preclinical data

...Data were presented at the American Society of Gene and Cell Therapy meeting in Washington. Virxsys Corp....
BioCentury | May 31, 2010
Clinical News

Lexgenleucel-T: Phase II data

...Data were presented at the American Society of Gene and Cell Therapy meeting in Washington. Virxsys Corp....
BioCentury | Feb 22, 2010
Clinical News

Lexgenleucel-T: Phase I/II data

...antiretroviral therapy. Data were presented at the Retroviruses and Opportunistic Infections meeting in San Francisco. Virxsys Corp....
BioCentury | Feb 22, 2010
Clinical News

Virxsys preclinical data

...Infections meeting in San Francisco. VRX1023 is an HIV-based lentiviral vector that delivers HIV antigens. Virxsys Corp....
BioCentury | Sep 17, 2009
Cover Story

Rational attack on HIV

...broader response involving other immune cells. Gary McGarrity, EVP of scientific and clinical affairs at Virxsys Corp....
...have antibodies in the serum, but are they present on the mucosal surface?" he asked. Virxsys'...
...gp120 epitope identified by the IAVI team is within the viral genome region targeted by Virxsys'...
BioCentury | Feb 16, 2009
Clinical News

Lexgenleucel-T: Phase I/II data

...modified cells. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Montreal. Virxsys Corp....
Items per page:
1 - 10 of 31